Eqt Life Sciences

Plus: Flagship unveils disease interception play Etiome; Verastem raises $75M PIPE; and more

Panelists on a Capital Markets Preview webinar from BioCentury and Oppenheimer debate the hottest trend in dealmaking

In BioCentury’s Venture Report: Oncomatryx, Quibin raise cash in Spain; Atalanta draws $97M; Forbion’s BioEconomy Fund

Plus: Amphista names Paul Medeiro CBO, and updates from Apellis, Forbion, Eqt, Egle, Spero, Molecular Templates and more

BioCentury’s Financial Report also includes new biotech foundry Jupiter, and public equity fundings for Spyre, Cidara and Aclaris

Plus: Hwang joins Metaphore, Flagship and updates from FDA, MHRA, ArrePath, ABT, Unnatural, Thryv and more

So far in 2024, at least 25 firms have raised $17.3B in new VC funds, with 11 exceeding $500M

Only nine other biotechs have raised over $25 million since 2015

Plus: Rounds for Radiant, Vironexis, Bambusa, OrsoBio and F2G

Back to School 2024: Investments in AI in drug discovery pick up, as the picture starts to form of how target discovery may benefit